Want to create an interactive transcript for this episode?
Podcast: iForumRx.org
Episode: Why is Thor’s Hammer, Molnupiravir, Considered a 4th Line Option for COVID-19?
Description: Two novel oral antiviral agents were granted emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in late December 2021. Although it is named after Thor’s hammer, Mjölnir, molnupiravir was given a last place (4th line) recommendation by the National Institutes of Health (NIH) COVID-19 Treatment Guideline Panel. What gives?
Guest Authors: Amanda Applegate, PharmD, BCACP and Mary Beth Dameron, PharmD, BCACP
Music by Good Talk